Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Medical - Instruments & Supplies

Healthcare
$3.60 +2.30%

+$0.37 today

Market cap
$158.01M
Beta
4.34
P/E (TTM)
99.1
EPS (TTM)
$0.16
52W Low $10.50High $55.65

Volume 0.09M

Average 0.03M

NNNN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN

EBITDA · Q4 FY2025 · quarter ended Dec 2025

EBITDA turns positive

Q4 FY2025 EBITDA was $2.8M, compared with -$1.32M a year earlier. Over 3 fiscal years it compounded at -13.4% a year.

Context

  • EBITDA amounted to 66.7% of revenue in FY2025, up 35.3 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$2.8M— QoQ
Last fiscal yearDec 2025
$6.51M+153.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+311.3%——
1 year+153.6%——
3-year CAGR-13.4%——
5-year CAGR——
10-year CAGR——

EBITDA history

USD · from the income statement

Latest · FY2025
6.51M USD
Year-over-year change
+153.6%
4-year CAGR
+26.6%

EBITDA vs competitors

How NNNN compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +153.6% is the 4th highest of 10, against a peer median of +44.4%.
  • EBITDA amounts to 66.7% of revenue for NNNN, versus a peer median of 23.1%.
NNNN Competitors
EBITDA for NNNN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CYHCommunity Health Systems, Inc.LTM Mar 2026$4.96B USD+296.6%+20.0%23.1%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$131.28M USD+170.9%—43.8%
SNDLSNDL Inc.LTM Mar 2026CA$49.42M CAD+201.3%—5.3%
NNNNAnbio Biotechnology Class A Ordinary SharesFY2025$6.51M USD+153.6%-13.4%66.7%
TALKTalkspace, Inc.LTM Mar 2026$6.2M USD+44.4%—2.6%
ANGOAngioDynamics, Inc.LTM Feb 2026-$5.44M USD-1089.6%-46.2%1.7%
AVNSAvanos Medical, Inc.LTM Mar 2026-$21.6M USD+93.7%—3.0%
CLPTClearPoint Neuro, Inc.LTM Mar 2026-$23.66M USD-24.4%—58.2%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-$117.15M USD——101.1%
GOSSGossamer Bio, Inc.LTM Mar 2026-$168.81M USD-372.8%—304.0%
CMPSCOMPASS Pathways plcLTM Mar 2026-$176.6M USD-34.4%——
Peer median (excluding NNNN) —+44.4%-13.1%23.1%

Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.43M23.54M6.71M8.19M9.76M
Cost of Revenue1.89M10.98M3.35M2.3M1.25M
Gross Profit2.54M12.56M3.36M5.89M8.51M
Gross Margin57.4%53.4%50.1%71.9%87.2%
Research & Development0200K134.7K454.23K227.19K
Selling, General & Admin86.1K2.17M1.27M3.44M1.78M
Operating Expenses86.1K2.37M1.4M3.89M2M
Depreciation & Amortization06.25K13.04K00
EBITDA2.54M10.03M2.27M2.57M6.51M
EBITDA Margin57.3%42.6%33.8%31.4%66.7%
Operating Income2.46M10.2M1.96M2M6.51M
Operating Margin55.5%43.3%29.2%24.4%66.7%
Interest Income042.25K165.34K337.51K160.28K
Interest Expense08K000
Other Income / Expenses79.94K(184.41K)292.78K377.48K717.46K
Income Before Tax2.54M10.01M2.25M2.37M7.23M
Pre-Tax Margin57.3%42.5%33.6%29.0%74.1%
Income Tax Expense00000
Net Income2.54M10.01M2.25M2.37M7.23M
Net Margin57.3%42.5%33.6%29.0%74.1%
EPS (Basic)0.030.070.020.060.16
EPS (Diluted)0.030.070.010.060.16
Weighted Avg Shares100M143.89M143.89M42.29M43.89M
Weighted Avg Shares (Diluted)100M143.89M187.78M42.29M43.89M

Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Intrinsic Alpha fair value

Locked

Current Price

$3.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.